In Article #4, we established that data governance is a clinical safety issue: that what feeds an algorithm determines what it produces, and that a data pipeline with no oversight is a direct path to a bad outcome.
This article looks at one specific, common way that plays out: a model that performs beautifully overall, and quietly worse for the patients it was never properly tested on.
(Governing the Algorithm, Article #5)
A Strong Headline Number Can Hide a Real Problem
An algorithm with 95% overall accuracy sounds validated. But an aggregate performance number is an average, and averages are exactly where subgroup problems go to hide. A model can post excellent topline results while performing meaningfully worse for a specific age group, sex, skin tone, body habitus, or comorbidity profile, and the topline number will never reveal it.
The uncomfortable governance truth here isn't "the model is biased." It's narrower and more preventable than that:
If you didn't test for it, you don't know it's not there.
Why This Isn't Just a Technical Limitation
It's tempting to treat subgroup performance gaps as an unavoidable, purely technical limitation of machine learning: models learn from the data they're given, and real-world data is never perfectly balanced. That's true, but it's not the governance failure.
The governance failure is deploying a model into clinical use without ever explicitly testing whether such a gap exists, and without a plan for what happens if one is found later. A technical limitation is expected. An untested, undocumented, unmonitored limitation is a governance gap.
What Subgroup Testing Actually Requires
✔ Defined subgroups relevant to the clinical use case: not just broad demographic categories, but the specific factors plausibly relevant to how the device performs (imaging equipment variation, disease prevalence differences, anatomical variation, etc.)
✔ Adequate sample size per subgroup: a subgroup with a handful of cases in the validation set doesn't produce a meaningful performance estimate, even if it technically "was included"
✔ Documented results, not just a pass/fail summary: a governance-ready validation shows subgroup performance explicitly, including where it's weaker, rather than only reporting an aggregate that obscures it
✔ A defined response if a gap is found: additional data collection, labeling restrictions, post-market monitoring commitments, or a documented limitation disclosed to users
Most companies do some version of the first item. Very few do all four, and the fourth is often where governance either becomes real or stays theoretical.
Why Hospitals Are Starting to Ask This Directly
"Has this been validated across the populations we actually serve?"
This question is becoming standard in more sophisticated procurement processes, particularly at academic medical centers and safety-net hospitals serving diverse patient populations. A vendor who can answer with subgroup-specific data is treated very differently from one who can only point to an aggregate number. Regardless of how good that aggregate number is.
Final Thought
An untested subgroup gap isn't evidence the model is unsafe. It's evidence nobody has checked.
Aggregate performance proves the model works on average.
Subgroup testing proves it works for the actual patient in front of the clinician.
The gap between those two claims is exactly where undetected bias lives: and closing it is a governance decision, made before deployment, not a technical fix applied after a complaint.
Next in the Governing the Algorithm Series:
Model Drift Is Inevitable. Undetected Model Drift Is Negligence.
#HealthcareAI #DataGovernance #Bias #HealthEquity #SaMD #RiskManagement #Compliance #DigitalHealth #HealthcareInnovation #ArtificialIntelligence #MedTech #QscriptionTechnologies